Italy fines drug company for excessive pricing
Shutterstock/Planar
Italy’s Competition Authority has fined Leadiant Biosciences €3.5 million for abusing its dominance by overcharging the national health service for an orphan drug, less than a year after the Dutch antitrust enforcer penalised the drugmaker for the same conduct.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now